|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||124.02 - 125.66|
|52 Week Range||106.23 - 136.83|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.
Gilead Sciences' (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.
Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank #1, 2 or 3 would lead to profits in investor portfolios.
Allergan (AGN) is a US-based pharmaceuticals company that deals in over-the-counter products, eye care products, and aesthetics products.
Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: ...
Todd Hagopian’s Biotech Fund is up over 30% as many of his stock picks have taken off after President Trump and Senate Republicans turned their attention to healthcare.
With names like AbbVie and Celgene on a tear the past week, many biotech sector ETFs hit 52-week or longer highs.
Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.
As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. In April 2017, Ionis entered into…
Daniel Schwartz, York Capital Management co-CEO, weighs in on the strength of the M&A market and where he sees the biggest opportunities, including biotechnology and the telecom industry.
Mark Alles, Celgene CEO, talks about the importance of forming a partnership between innovators and insurance companies in order to provide patients with access to precision medicines.
Mark Alles, Celgene CEO, talks about gaining FDA approval for a drug that targets a lethal form of leukemia and discusses the importance of getting patients access to precision medicines.